Industry top-down
Biotechnology
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The biotechnology industry exhibited significant disparities in sales performance across companies. While some companies achieved high sales growth rates of over 40%, others experienced double-digit sales declines. The industry's median sales growth rate stood at approximately 19.2%, though this figure reflects the varied performance of individual companies. Limited EPS data makes it difficult to ascertain overall profitability trends.
- Some companies achieved high revenue growth rates
- Other companies experienced revenue decline or stagnation
- Lack of EPS data limits profitability assessment
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| VRTXVERTEX PHARMACEUTICALS INC / MA | FY2026 Q2 | $3.33B | +12.5% | $4.31 | +8.0% | — |
| REGNREGENERON PHARMACEUTICALS, INC. | FY2026 Q2 | $4.29B | +16.7% | $12.23 | -4.5% | — |
| MRNAModerna, Inc. | FY2026 Q2 | $145M | +2.1% | $-1.97 | — | — |
| 207940SAMSUNG BIOLOGICS CO.,LTD. | FY2025 Q3 | ₩1.66T | +39.9% | ₩8071.00 | +117.2% | — |
| RVMDRevolution Medicines, Inc. | FY2024 Q3 | $0 | — | $-0.94 | — | — |
| ONCBeOne Medicines Ltd. | FY2026 Q2 | $1.71B | +29.6% | $0.16 | +166.7% | — |
| ALNYALNYLAM PHARMACEUTICALS, INC. | FY2026 Q2 | $1.29B | +66.9% | $1.21 | — | — |
| RPRXRoyalty Pharma plc | FY2026 Q2 | $674.14M | +16.5% | $0.04 | -42.9% | — |
| BEIGFBeOne Medicines Ltd. | FY2026 Q2 | $1.71B | +29.6% | $0.16 | +166.7% | — |
| 068270Celltrion, Inc. | FY2026 Q2 | ₩1.39T | +45.0% | ₩1609.00 | — | — |
| ROIVRoivant Sciences Ltd. | FY2027 Q1 | $1.44M | -33.5% | $-0.26 | — | — |
| INSMINSMED Inc | FY2026 Q2 | $425.49M | +296.1% | $-0.06 | — | — |
| INCYINCYTE CORP | FY2026 Q1 | $1.27B | +20.9% | $1.47 | +83.7% | — |
| JAZZJazz Pharmaceuticals plc | FY2026 Q2 | $1.21B | +15.5% | $2.78 | — | — |
| EXELEXELIXIS, INC. | FY2027 Q2 | $628.69M | +10.6% | $0.82 | +26.2% | — |
| HALOHALOZYME THERAPEUTICS, INC. | FY2026 Q2 | $481M | +47.7% | $1.90 | +42.9% | — |
| 196170Alteogen Inc. | FY2026 Q2 | ₩68.89B | +269.5% | ₩531.00 | — | — |
| BBIOBridgeBio Pharma, Inc. | FY2026 Q2 | $243.68M | +120.4% | $-0.78 | — | — |
| CORTCORCEPT THERAPEUTICS INC | FY2026 Q2 | $256.15M | +31.7% | $0.36 | +24.1% | — |
| SMMTSummit Therapeutics Inc. | FY2024 Q3 | $0 | — | $-0.08 | — | — |
| MDGLMADRIGAL PHARMACEUTICALS, INC. | FY2026 Q2 | $364.25M | +71.2% | $-1.99 | — | — |
| BMRNBIOMARIN PHARMACEUTICAL INC | FY2026 Q2 | $989.71M | +19.9% | $0.23 | -81.3% | — |
| TECHBIO-TECHNE Corp | FY2026 Q3 | $311.42M | -1.5% | $0.32 | +128.6% | — |
| KRYSKrystal Biotech, Inc. | FY2026 Q2 | $119.22M | +24.1% | $1.79 | +38.8% | — |
| AXSMAxsome Therapeutics, Inc. | FY2026 Q2 | $218.38M | +45.5% | $-0.99 | — | — |
| ARWRARROWHEAD PHARMACEUTICALS, INC. | FY2026 Q3 | $75.25M | +171.0% | $-1.36 | — | — |
| KYMRKymera Therapeutics, Inc. | FY2026 Q2 | $65M | — | $-0.62 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).